Radiotherapy for Extracranial Oligometastatic Breast Cancer

More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic therapy alone, on survival, local control and toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three factors: visceral metastasis (yes vs.no), number of met

Trial Details

NCT ID
NCT04646564
Phase
PHASE3
Sponsor
Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • standard of care
  • radiotherapy + standard of care
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Taizhou, Zhejiang, China|28.66266,121.43312

Key Eligibility Criteria

  • 18-70 years old
  • ECOG performance status 0-2.
  • Newly-diagnosed or metachronous extracranial oligometastatic diseases confirmed by pathology or imaging, with or without locoregional disease (biop…
  • Total number of locoregional and metastatic lesions of 1-5 , the maximum diameter of lesions ≤5 cm and at least one lesion could be evaluated by RE…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →